• ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blog
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  • ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blog
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  1. Home
  2. Services
  3. Clinical Pharmacology Modeling Simulation
  4. Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
  5. Noncompartmental PK Analysis (NCA)
    • Data Management, Programming, and CDISC Dataset Creation
    • Noncompartmental PK Analysis (NCA)
    • Population Pharmacokinetics (popPK)

Noncompartmental PK Analysis (NCA)

  • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
  • Data Management, Programming, and CDISC Dataset Creation
  • Noncompartmental PK Analysis (NCA)
  • Population Pharmacokinetics (popPK)

Noncompartmental PK analysis (NCA) is a standard, efficient, and effective method for estimating PK parameters and is indispensable for characterizing PK within a single study and for making time-critical dosing decisions (e.g., within dose escalation trials). Parameters from NCAs are also routinely used by regulatory authorities to inform their decision making both during development and during the approval process. Allucent will make sure your NCA is performed correctly and to the highest standard to ensure you get the most out of your data, setting your program up for success.

What is NCA?

NCA is a type of analysis that provides the most elementary pharmacokinetic (PK) information for a drug (i.e., peak concentration and elimination half-life). NCAs are essential for characterizing new drug products and can help guide drug development at each stage. NCAs often prove to be faster and more cost-efficient compared to more complex compartmental analyses (e.g., population PK analyses). As the name would imply, noncompartmental analyses do not rely upon assumptions about bodily compartments. In addition, NCAs rely almost exclusively upon simple algebraic equations to estimate PK parameters, making the analysis less complex than compartmental methods.

When to Use NCA

Deciding whether to use an NCA versus a compartmental approach is not a function of how sophisticated the method is but really depends upon the purpose of the analysis and the design of the study. NCAs require rich sampling across the entire concentration versus time profile and are most commonly utilized in early phase or clinical pharmacology studies. Compartmental models can integrate both rich and sparse sampling and are often utilized to analyze Phase 2 and 3 studies with fewer samples per subject.

NCAs are typically favored for characterizing PK within a single study, including both final analyses and any interim analyses used to make dose escalation decisions. In addition, NCA is the most commonly used approach for establishing the initial exposure characteristics of a drug prior to entry into the clinic (i.e., during nonclinical PK and toxicology studies).

Contact Us

Let us partner with your team on bringing new therapies to light. Get in touch to get started.

CONTACT US

  • Services
    • Clinical Trial Operations
    • Regulatory and Drug Development Consulting
    • Government and Public Health Services
    • Biometrics
    • Clinical Pharmacology Modeling Simulation
  • Therapeutic Expertise
    • Oncology and Hematology
    • Rare Diseases and Orphan Drugs
    • Infectious Disease and Vaccine
    • Cell and Gene Therapy
    • Central Nervous System
    • Autoimmune and Inflammation
    • Allergy and Asthma
  • Company
    • About Us
    • News
    • Events
  • Privacy Policy
  • English
  • Francais

© 2023 Allucent. All rights

North American Headquarters
2000 Centregreen Way
Suite 300
Cary, North Carolina 27513
+1 919-361-2286

United Kingdom Headquarters
1st Floor, One Station Square,
Bracknell, Berkshire
RG12 1QB United Kingdom
T: +44 (0) 1344 891121
F: +44 (0) 1344 890335

European Headquarters
Stationsplein Noord-Oost 438
1117 CL Schiphol
The Netherlands
+31 20-4350-580